Table 5.
PH-related healthcare costs during the 12 months following index date in portal hypertension patients with PH (n = 146).
| Annual per-patient costs, $ (inflation -adjusted to 2018 US dollars) | |
|---|---|
| PH-related hospitalizations | |
| Mean (SD) | 18,800 (49,019) |
| Median (IQR) | 0 (0–17,686) |
| PH-related ER visits | |
| Mean (SD) | 2854 (18,955) |
| Median (IQR) | 0 (0–0) |
| PH-related outpatient office/clinic services | |
| Mean (SD) | 133.42 (288) |
| Median (IQR) | 0 (0–118) |
| PH-related pharmacy* | |
| Mean (SD) | 14,190 (46,901) |
| Median (IQR) | 0 (0–0) |
| PH-related medical costs† | |
| Mean (SD) | 27,613 (62,216) |
| Median (IQR) | 5183 (727–30,819) |
| PH-related healthcare costs‡ | |
| Mean (SD) | 41,803 (81,818) |
| Median (IQR) | 6593 (727–38,331) |
ER: emergency room; IQR: interquartile range; PH: pulmonary hypertension; SD: standard deviation.
*
Sum of pharmacy claims for any of the following medications: endothelin receptor antagonists, phosphodiesterase type-5 inhibitors, prostacyclin-pathway drugs, and soluble guanylate cyclase stimulator.
†
Sum of costs for hospital admission, outpatient office/clinic, ER, long-term care facility, skilled nursing facility, rehabilitation, and other medical services.
‡
Sum of costs for all medical services and pharmacy claims.